Emerging anticoagulants

Current Medicinal Chemistry

Volumn 19, Issue 20, 2012, Pages 3388-3416

  Kennedy, B ^a   Gargoum, F S ^a   Kennedy, L ^b   Khan, F ^a   Curran, D R ^a   O'Connor, T M ^a  

^a MERCY UNIVERSITY HOSPITAL   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Anticoagulants; Heparin; Thrombin; Warfarin

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; BETRIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; CLOPIDOGREL; DALTEPARIN; DAREXABAN; EDOXABAN; ENOXAPARIN; EPTIFIBATIDE; FONDAPARINUX; GEFITINIB; HEPARIN; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; IDRABIOTAPARINUX; IDRAPARINUX; KETOCONAZOLE; LETAXABAN; LIXIANA; N [2 [4 (1 METHYL 4 PIPERIDINYL) 1 PIPERAZINYL] 2 OXO 1 PHENYLETHYL] 1H INDOLE 6 CARBOXAMIDE; OTAMIXABAN; PHENPROCOUMON; PLACEBO; PROTAMINE SULFATE; PYRROLE; RIVAROXABAN; TINZAPARIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; BLEEDING; BRAIN HEMORRHAGE; CORONARY ARTERY DISEASE; DEEP VEIN THROMBOSIS; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HEART MUSCLE ISCHEMIA; HEMOSTASIS; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; LUNG EMBOLISM; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; NONHUMAN; ORTHOPEDIC SURGERY; OSTEOPOROSIS; PROPHYLAXIS; REVIEW; SINGLE DRUG DOSE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STROKE; THROMBOCYTOPENIA; VENOUS THROMBOEMBOLISM;

ANIMALS; ANTICOAGULANTS; FACTOR XA; HEMOSTASIS; HUMANS; THROMBIN;

EID: 84863760503     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712801215847     Document Type: Review

References (182)

1. White, R. H., The epidemiology of venous thromboembolism. Circulation 2003, 107 (23 Suppl 1), I4-8.
2. Cohen, A. T.; Agnelli, G.; Anderson, F. A.; Arcelus, J. I.; Bergqvist, D.; Brecht, J. G.; Greer, I. A.; Heit, J. A.; Hutchinson, J. L.; Kakkar, A. K.; Mottier, D.; Oger, E.; Samama, M. M.; Spannagl, M., Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 2007, 98 (4), 756-64.
3. Hylek, E. M., Therapeutic potential of oral factor Xa inhibitors. N Engl J Med 2010, 363 (26), 2559-61.
4. Kahn, S. R.; Ginsberg, J. S., Relationship between deep venous thrombosis and the postthrombotic syndrome. Arch Intern Med 2004, 164 (1), 17-26.
5. Pengo, V.; Lensing, A. W.; Prins, M. H.; Marchiori, A.; Davidson, B. L.; Tiozzo, F.; Albanese, P.; Biasiolo, A.; Pegoraro, C.; Iliceto, S.; Prandoni, P., Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004, 350 (22), 2257-64.
6. Piazza, G.; Goldhaber, S. Z., Chronic thromboembolic pulmonary hypertension. N Engl J Med 2011, 364 (4), 351-60.
7. Saouti, N.; de Man, F.; Westerhof, N.; Boonstra, A.; Twisk, J.; Postmus, P. E.; Vonk Noordegraaf, A., Predictors of mortality in inoperable chronic thromboembolic pulmonary hypertension. Respir Med 2009, 103 (7), 1013-9.
8. Mahan, C. E.; Holdsworth, M. T.; Welch, S. M.; Borrego, M.; Spyropoulos, A. C., Deep-vein thrombosis: a United States cost model for a preventable and costly adverse event. Thromb Haemost 2011, 106 (3), 405-15.
9. Kearon, C.; Kahn, S. R.; Agnelli, G.; Goldhaber, S.; Raskob, G. E.; Comerota, A. J., Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133 (6 Suppl), 454S-545S.
10. Harrington, R. A.; Becker, R. C.; Cannon, C. P.; Gutterman, D.; Lincoff, A. M.; Popma, J. J.; Steg, G.; Guyatt, G. H.; Goodman, S. G., Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133 (6 Suppl), 670S-707S.
11. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994, 154 (13), 1449-57.
12. Schulman, S.; Beyth, R. J.; Kearon, C.; Levine, M. N., Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133 (6 Suppl), 257S-298S.
13. Geerts, W. H.; Bergqvist, D.; Pineo, G. F.; Heit, J. A.; Samama, C. M.; Lassen, M. R.; Colwell, C. W., Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133 (6 Suppl), 381S-453S.
14. (a) Deheinzelin, D.; Braga, A. L.; Martins, L. C.; Martins, M. A.; Hernandez, A.; Yoshida, W. B.; Maffei, F.; Monachini, M.; Calderaro, D.; Campos, W., Jr.; Sguizzatto, G. T.; Caramelli, B., Incorrect use of thromboprophylaxis for venous thromboembolism in medical and surgical patients: results of a multicentric, observational and cross-sectional study in Brazil. J Thromb Haemost 2006, 4 (6), 1266-70
15. (b) Khoury, H.; Welner, S.; Kubin, M.; Folkerts, K.; Haas, S., Disease burden and unmet needs for prevention of venous thromboembolism in medically ill patients in Europe show underutilisation of preventive therapies. Thromb Haemost 2011, 106 (4), 600-8.
16. Amin, A.; Stemkowski, S.; Lin, J.; Yang, G., Thromboprophylaxis rates in US medical centers: success or failure? J Thromb Haemost 2007, 5 (8), 1610-6.
17. Dahlback, B., Blood coagulation. Lancet 2000, 355 (9215), 1627-32.
18. Furie, B.; Furie, B. C., Molecular and cellular biology of blood coagulation. N Engl J Med 1992, 326 (12), 800-6.
19. Woodruff, R. S.; Sullenger, B.; Becker, R. C., The many faces of the contact pathway and their role in thrombosis. J Thromb Thrombolysis 2011, 32 (1), 9-20.
20. Esmon, C. T., The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 1989, 264 (9), 4743-6.
21. Mavrakanas, T.; Bounameaux, H., The potential role of new oral anticoagulants in the prevention and treatment of thromboembolism. Pharmacol Ther 2011, 130 (1), 46-58.
22. Hirsh, J.; Bauer, K. A.; Donati, M. B.; Gould, M.; Samama, M. M.; Weitz, J. I., Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133 (6 Suppl), 141S-159S.
23. Hirsh, J.; Warkentin, T. E.; Raschke, R.; Granger, C.; Ohman, E. M.; Dalen, J. E., Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1998, 114 (5 Suppl), 489S-510S.
24. Ansell, J.; Hirsh, J.; Hylek, E.; Jacobson, A.; Crowther, M.; Palareti, G., Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133 (6 Suppl), 160S-198S.
25. Wong, P. C.; Pinto, D. J.; Zhang, D., Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor. J Thromb Thrombolysis 2011, 31 (4), 478-92.
26. Raghavan, N.; Frost, C. E.; Yu, Z.; He, K.; Zhang, H.; Humphreys, W. G.; Pinto, D.; Chen, S.; Bonacorsi, S.; Wong, P. C.; Zhang, D., Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 2009, 37 (1), 74-81.
27. Ufer, M., Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb Haemost 2010, 103 (3), 572-85.
28. Wang, L.; Zhang, D.; Raghavan, N.; Yao, M.; Ma, L.; Frost, C. E.; Maxwell, B. D.; Chen, S. Y.; He, K.; Goosen, T. C.; Humphreys, W. G.; Grossman, S. J., In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos 2010, 38 (3), 448-58.
29. Jiang, X.; Crain, E. J.; Luettgen, J. M.; Schumacher, W. A.; Wong, P. C., Apixaban, an oral direct factor Xa inhibitor, inhibits human clot-bound factor Xa activity in vitro. Thromb Haemost 2009, 101 (4), 780-2.
30. Lassen, M. R.; Raskob, G. E.; Gallus, A.; Pineo, G.; Chen, D.; Portman, R. J., Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009, 361 (6), 594-604.
31. Lassen, M. R.; Raskob, G. E.; Gallus, A.; Pineo, G.; Chen, D.; Hornick, P., Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010, 375 (9717), 807-15.
32. Lassen, M. R.; Gallus, A.; Raskob, G. E.; Pineo, G.; Chen, D.; Ramirez, L. M., Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010, 363 (26), 2487-98.
33. Falck-Ytter, Y.; Francis, C. W.; Johanson, N. A.; Curley, C.; Dahl, O. E.; Schulman, S.; Ortel, T. L.; Pauker, S. G.; Colwell, C. W., Jr., Prevention of VTE in Orthopedic Surgery Patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141 (2 Suppl), e278S-325S.
34. Watson, J.; Whiteside, G.; Perry, C., Apixaban: first global approval. Drugs 2011, 71 (15), 2079-89.
35. Goldhaber, S. Z.; Leizorovicz, A.; Kakkar, A. K.; Haas, S. K.; Merli, G.; Knabb, R. M.; Weitz, J. I., Apixaban versus Enoxaparin for Thromboprophylaxis in Medically Ill Patients. N Engl J Med 2011.
36. Buller, H.; Deitchman, D.; Prins, M.; Segers, A., Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost 2008, 6 (8), 1313-8.
37. Connolly, S. J.; Eikelboom, J.; Joyner, C.; Diener, H. C.; Hart, R.; Golitsyn, S.; Flaker, G.; Avezum, A.; Hohnloser, S. H.; Diaz, R.; Talajic, M.; Zhu, J.; Pais, P.; Budaj, A.; Parkhomenko, A.; Jansky, P.; Commerford, P.; Tan, R. S.; Sim, K. H.; Lewis, B. S.; Van Mieghem, W.; Lip, G. Y.; Kim, J. H.; Lanas-Zanetti, F.; Gonzalez-Hermosillo, A.; Dans, A. L.; Munawar, M.; O'Donnell, M.; Lawrence, J.; Lewis, G.; Afzal, R.; Yusuf, S., Apixaban in patients with atrial fibrillation. N Engl J Med 2011, 364 (9), 806-17.
38. Granger, C. B.; Alexander, J. H.; McMurray, J. J.; Lopes, R. D.; Hylek, E. M.; Hanna, M.; Al-Khalidi, H. R.; Ansell, J.; Atar, D.; Avezum, A.; Bahit, M. C.; Diaz, R.; Easton, J. D.; Ezekowitz, J. A.; Flaker, G.; Garcia, D.; Geraldes, M.; Gersh, B. J.; Golitsyn, S.; Goto, S.; Hermosillo, A. G.; Hohnloser, S. H.; Horowitz, J.; Mohan, P.; Jansky, P.; Lewis, B. S.; Lopez-Sendon, J. L.; Pais, P.; Parkhomenko, A.; Verheugt, F. W.; Zhu, J.; Wallentin, L., Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011, 365 (11), 981-92.
39. You, J. J.; Singer, D. E.; Howard, P. A.; Lane, D. A.; Eckman, M. H.; Fang, M. C.; Hylek, E. M.; Schulman, S.; Go, A. S.; Hughes, M.; Spencer, F. A.; Manning, W. J.; Halperin, J. L.; Lip, G. Y., Antithrombotic Therapy for Atrial Fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141 (2 Suppl), e531S-75S.
40. Alexander, J. H.; Lopes, R. D.; James, S.; Kilaru, R.; He, Y.; Mohan, P.; Bhatt, D. L.; Goodman, S.; Verheugt, F. W.; Flather, M.; Huber, K.; Liaw, D.; Husted, S. E.; Lopez-Sendon, J.; De Caterina, R.; Jansky, P.; Darius, H.; Vinereanu, D.; Cornel, J. H.; Cools, F.; Atar, D.; Leiva-Pons, J. L.; Keltai, M.; Ogawa, H.; Pais, P.; Parkhomenko, A.; Ruzyllo, W.; Diaz, R.; White, H.; Ruda, M.; Geraldes, M.; Lawrence, J.; Harrington, R. A.; Wallentin, L., Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011, 365 (8), 699-708.
41. Perzborn, E.; Roehrig, S.; Straub, A.; Kubitza, D.; Mueck, W.; Laux, V., Rivaroxaban: a new oral factor Xa inhibitor. Arterioscler Thromb Vasc Biol 2010, 30 (3), 376-81.
42. Kubitza, D.; Becka, M.; Voith, B.; Zuehlsdorf, M.; Wensing, G., Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 2005, 78 (4), 412-21.
43. Eriksson, B. I.; Borris, L. C.; Friedman, R. J.; Haas, S.; Huisman, M. V.; Kakkar, A. K.; Bandel, T. J.; Beckmann, H.; Muehlhofer, E.; Misselwitz, F.; Geerts, W., Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008, 358 (26), 2765-75.
44. Kakkar, A. K.; Brenner, B.; Dahl, O. E.; Eriksson, B. I.; Mouret, P.; Muntz, J.; Soglian, A. G.; Pap, A. F.; Misselwitz, F.; Haas, S., Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008, 372 (9632), 31-9.
45. Lassen, M. R.; Ageno, W.; Borris, L. C.; Lieberman, J. R.; Rosencher, N.; Bandel, T. J.; Misselwitz, F.; Turpie, A. G., Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008, 358 (26), 2776-86.
46. Turpie, A. G.; Lassen, M. R.; Davidson, B. L.; Bauer, K. A.; Gent, M.; Kwong, L. M.; Cushner, F. D.; Lotke, P. A.; Berkowitz, S. D.; Bandel, T. J.; Benson, A.; Misselwitz, F.; Fisher, W. D., Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009, 373 (9676), 1673-80.
47. Turpie, A. G.; Lassen, M. R.; Eriksson, B. I.; Gent, M.; Berkowitz, S. D.; Misselwitz, F.; Bandel, T. J.; Homering, M.; Westermeier, T.; Kakkar, A. K., Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb Haemost 2011, 105 (3), 444-53.
48. Cohen, A. T.; Spiro, T. E.; Buller, H. R.; Haskell, L.; Hu, D.; Hull, R.; Mebazaa, A.; Merli, G.; Schellong, S.; Spyropoulos, A.; Tapson, V., Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol. J Thromb Thrombolysis 2011, 31 (4), 407-16.
49. . In the Prevention of VTE in Acutely ill Patients, Rivaroxaban Compares Favorably with Enoxaparin but Does Not Show a Consistent Net Clinical Benefit BAYNEWS [Online]. http://www.press.bayer.com/baynews/baynews. nsf/0/AF823C5EA4152146C125786900252259?Open&setprintmode=1 (accessed 08/12/2011).
50. Bauersachs, R.; Berkowitz, S. D.; Brenner, B.; Buller, H. R.; Decousus, H.; Gallus, A. S.; Lensing, A. W.; Misselwitz, F.; Prins, M. H.; Raskob, G. E.; Segers, A.; Verhamme, P.; Wells, P.; Agnelli, G.; Bounameaux, H.; Cohen, A.; Davidson, B. L.; Piovella, F.; Schellong, S., Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010, 363 (26), 2499-510.
51. Kearon, C.; Akl, E. A.; Comerota, A. J.; Prandoni, P.; Bounameaux, H.; Goldhaber, S. Z.; Nelson, M. E.; Wells, P. S.; Gould, M. K.; Dentali, F.; Crowther, M.; Kahn, S. R., Antithrombotic Therapy for VTE Disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141 (2 Suppl), e419S-94S.
52. Patel, M. R.; Mahaffey, K. W.; Garg, J.; Pan, G.; Singer, D. E.; Hacke, W.; Breithardt, G.; Halperin, J. L.; Hankey, G. J.; Piccini, J. P.; Becker, R. C.; Nessel, C. C.; Paolini, J. F.; Berkowitz, S. D.; Fox, K. A.; Califf, R. M., Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011, 365 (10), 883-91.
53. Mega, J. L.; Braunwald, E.; Mohanavelu, S.; Burton, P.; Poulter, R.; Misselwitz, F.; Hricak, V.; Barnathan, E. S.; Bordes, P.; Witkowski, A.; Markov, V.; Oppenheimer, L.; Gibson, C. M., Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 2009, 374 (9683), 29-38.
54. Mega, J. L.; Braunwald, E.; Wiviott, S. D.; Bassand, J. P.; Bhatt, D. L.; Bode, C.; Burton, P.; Cohen, M.; Cook-Bruns, N.; Fox, K. A.; Goto, S.; Murphy, S. A.; Plotnikov, A. N.; Schneider, D.; Sun, X.; Verheugt, F. W.; Gibson, C. M., Rivaroxaban in Patients with a Recent Acute Coronary Syndrome. N Engl J Med 2011.
55. Paccaly, A.; Frick, A.; Rohatagi, S.; Liu, J.; Shukla, U.; Rosenburg, R.; Hinder, M.; Jensen, B. K., Pharmacokinetics of otamixaban, a direct factor Xa inhibitor, in healthy male subjects: pharmacokinetic model development for phase 2/3 simulation of exposure. J Clin Pharmacol 2006, 46 (1), 37-44.
56. Chu, V.; Brown, K.; Colussi, D.; Gao, J.; Bostwick, J.; Kasiewski, C.; Bentley, R.; Morgan, S.; Guertin, K.; Pauls, H. W.; Gong, Y.; Zulli, A.; Perrone, M. H.; Dunwiddie, C. T.; Leadley, R. J., Pharmacological characterization of a novel factor Xa inhibitor, FXV673. Thromb Res 2001, 103 (4), 309-24.
57. Cohen, M.; Bhatt, D. L.; Alexander, J. H.; Montalescot, G.; Bode, C.; Henry, T.; Tamby, J. F.; Saaiman, J.; Simek, S.; De Swart, J., Randomized, doubleblind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIAPCI trial. Circulation 2007, 115 (20), 2642-51.
58. Sabatine, M. S.; Antman, E. M.; Widimsky, P.; Ebrahim, I. O.; Kiss, R. G.; Saaiman, A.; Polasek, R.; Contant, C. F.; McCabe, C. H.; Braunwald, E., Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial. Lancet 2009, 374 (9692), 787-95.
59. Turpie, A. G., New oral anticoagulants in atrial fibrillation. Eur Heart J 2008, 29 (2), 155-65.
60. Turpie, A. G.; Bauer, K. A.; Davidson, B. L.; Fisher, W. D.; Gent, M.; Huo, M. H.; Sinha, U.; Gretler, D. D., A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT). Thromb Haemost 2009, 101 (1), 68-76.
61. Ogata, K.; Mendell-Harary, J.; Tachibana, M.; Masumoto, H.; Oguma, T.; Kojima, M.; Kunitada, S., Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 2010, 50 (7), 743-53.
62. Furugohri, T.; Isobe, K.; Honda, Y.; Kamisato-Matsumoto, C.; Sugiyama, N.; Nagahara, T.; Morishima, Y.; Shibano, T., DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost 2008, 6 (9), 1542-9.
63. Raskob, G.; Cohen, A. T.; Eriksson, B. I.; Puskas, D.; Shi, M.; Bocanegra, T.; Weitz, J. I., Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study. Thromb Haemost 2010, 104 (3), 642-9.
64. Fuji, T.; Fujita, S.; Tachibana, S.; Kawai, Y., A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty. J Thromb Haemost 2010, 8 (11), 2458-68.
65. Partida, R. A.; Giugliano, R. P., Edoxaban: pharmacological principles, preclinical and early-phase clinical testing. Future Cardiol 2011, 7 (4), 459-70.
66. Fuji, T., Fujita, S., Tachibana, S., Kawai, Y,. Koretsune, Y., Yamashita, T., Nakamura, M., Efficacy and Safety of Edoxaban Versus Enoxaparin for the Prevention of Venous Thromboembolism Following Total Hip Arthroplasty: STARS J-V trial. Blood 2010, 116 (21).
67. Fuji, T., Fujita, S., Tachibana, S., Kawai, Y., Edoxaban Versus Enoxaparin for the Prevention of Venous Thromboembolism: Pooled Analysis of Venous Thromboembolism and Bleeding From STARS E-3 and STARS J-V. Blood 2011, 118 (21).
68. Weitz, J. I.; Connolly, S. J.; Patel, I.; Salazar, D.; Rohatagi, S.; Mendell, J.; Kastrissios, H.; Jin, J.; Kunitada, S., Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost 2010, 104 (3), 633-41.
69. Chung, N.; Jeon, H. K.; Lien, L. M.; Lai, W. T.; Tse, H. F.; Chung, W. S.; Lee, T. H.; Chen, S. A., Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation. Thromb Haemost 2011, 105 (3), 535-44.
70. Groenendaal-van de Meent, D., Heeringa, M., Kadokura, T., Verheggen, F., Strabach, G. Heinzerling, H., YM150, An Oral Direct Inhibitor of Factor Xa, Demonstrated a Predictable and Dose-Proportional Pharmacokinetic/Pharmacodynamic Profile After Single and Multiple Dosing: Results From Three Studies. Blood 2010, 116 (21).
71. Iwatsuki, Y., Shigenaga, T., Moritani, Y., Suzuki, M., Ishihara, T., Hirayama, F., Kawasaki, T., Biochemical and Pharmacological Profiles of YM150, an Oral Direct Factor Xa Inhibitor. Blood 2006, 108 (11).
72. Eriksson, B. I.; Turpie, A. G.; Lassen, M. R.; Prins, M. H.; Agnelli, G.; Kalebo, P.; Wetherill, G.; Wilpshaar, J. W.; Meems, L., Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2). J Thromb Haemost 2010, 8 (4), 714-21.
73. Steg, P. G.; Mehta, S. R.; Jukema, J. W.; Lip, G. Y.; Gibson, C. M.; Kovar, F.; Kala, P.; Garcia-Hernandez, A.; Renfurm, R. W.; Granger, C. B., RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. Eur Heart J 2011, 32 (20), 2541-54.
74. Stringer, F., Scott, G., Kupfer, S., Prescott, K., Jenkins, R., Harding, S., Cao, C., Kawamura, M., The pharmacokinetics and pharmacodynamics of TAK-442, an oral, direct factor Xa inhibitor following multiple dosing in healthy male subjects. British Journal of Clinical Pharmacology 2010, 70 (2), 305.
75. Kawamura, M.; Konishi, N.; Hiroe, K.; Shofuda, K.; Imaeda, Y.; Fujimoto, T.; Kubo, K., Antithrombotic and anticoagulant profiles of TAK-442, a novel factor Xa inhibitor, in a rabbit model of venous thrombosis. J Cardiovasc Pharmacol 2010, 56 (2), 156-61.
76. Weitz, J. I.; Cao, C.; Eriksson, B. I.; Fisher, W.; Kupfer, S.; Raskob, G.; Spaeder, J.; Turpie, A. G., A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery. Thromb Haemost 2010, 104 (6), 1150-7.
77. Turpie, A. G., Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscler Thromb Va sc Biol 2007, 27 (6), 1238-47.
78. Agnelli, G.; Haas, S.; Ginsberg, J. S.; Krueger, K. A.; Dmitrienko, A.; Brandt, J. T., A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement. J Thromb Haemost 2007, 5 (4), 746-53.
79. Huntington, J. A.; McCoy, A.; Belzar, K. J.; Pei, X. Y.; Gettins, P. G.; Carrell, R. W., The conformational activation of antithrombin. A 2.85-A structure of a fluorescein derivative reveals an electrostatic link between the hinge and heparin binding regions. J Biol Chem 2000, 275 (20), 15377-83.
80. Rosenberg, R. D.; Damus, P. S., The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem 1973, 248 (18), 6490-505.
81. McRae, S. J.; Ginsberg, J. S., New anticoagulants for the prevention and treatment of venous thromboembolism. Vasc Health Risk Manag 2005, 1 (1), 41-53.
82. Olson, S. T.; Bjork, I.; Sheffer, R.; Craig, P. A.; Shore, J. D.; Choay, J., Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement. J Biol Chem 1992, 267 (18), 12528-38.
83. Herbert, J. M.; Herault, J. P.; Bernat, A.; van Amsterdam, R. G.; Lormeau, J. C.; Petitou, M.; van Boeckel, C.; Hoffmann, P.; Meuleman, D. G., Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. Blood 1998, 91 (11), 4197-205.
84. Donat, F.; Duret, J. P.; Santoni, A.; Cariou, R.; Necciari, J.; Magnani, H.; de Greef, R., The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin Pharmacokinet 2002, 41 Suppl 2, 1-9.
85. Bauer, K. A., New pentasaccharides for prophylaxis of deep vein thrombosis: pharmacology. Chest 2003, 124 (6 Suppl), 364S-370S.
86. Beguin, S.; Choay, J.; Hemker, H. C., The action of a synthetic pentasaccharide on thrombin generation in whole plasma. Thromb Haemost 1989, 61 (3), 397-401.
87. Paolucci, F.; Clavies, M. C.; Donat, F.; Necciari, J., Fondaparinux sodium mechanism of action: identification of specific binding to purified and human plasma-derived proteins. Clin Pharmacokinet 2002, 41 Suppl 2, 11-8.
88. Depasse, F.; Gerotziafas, G. T.; Busson, J.; Van Dreden, P.; Samama, M. M., Assessment of three chromogenic and one clotting assays for the measurement of synthetic pentasaccharide fondaparinux (Arixtra) anti-Xa activity. J Thromb Haemost 2004, 2 (2), 346-8.
89. Gerotziafas, G. T.; Depasse, F.; Chakroun, T.; Samama, M. M.; Elalamy, I., Recombinant factor VIIa partially reverses the inhibitory effect of fondaparinux on thrombin generation after tissue factor activation in platelet rich plasma and whole blood. Thromb Haemost 2004, 91 (3), 531-7.
90. Turpie, A. G.; Bauer, K. A.; Eriksson, B. I.; Lassen, M. R., Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 2002, 359 (9319), 1721-6.
91. Lassen, M. R.; Bauer, K. A.; Eriksson, B. I.; Turpie, A. G., Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised doubleblind comparison. Lancet 2002, 359 (9319), 1715-20.
92. Eriksson, B. I.; Bauer, K. A.; Lassen, M. R.; Turpie, A. G., Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 2001, 345 (18), 1298-304.
93. Eriksson, B. I.; Lassen, M. R., Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study. Arch Intern Med 2003, 163 (11), 1337-42.
94. Bauer, K. A.; Eriksson, B. I.; Lassen, M. R.; Turpie, A. G., Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001, 345 (18), 1305-10.
95. Turpie, A. G.; Bauer, K. A.; Eriksson, B. I.; Lassen, M. R., Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002, 162 (16), 1833-40.
96. Farias-Eisner, R.; Horblyuk, R.; Franklin, M.; Lunacsek, O. E.; Happe, L. E., Economic and clinical evaluation of fondaparinux vs. enoxaparin for thromboprophylaxis following general surgery. Curr Med Res Opin 2009, 25 (5), 1081-7.
97. Cohen, A. T.; Davidson, B. L.; Gallus, A. S.; Lassen, M. R.; Prins, M. H.; Tomkowski, W.; Turpie, A. G.; Egberts, J. F.; Lensing, A. W., Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 2006, 332 (7537), 325-9.
98. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti-factor Xa activity: A phase II evaluation. The Rembrandt Investigators. Circulation 2000, 102 (22), 2726-31.
99. Buller, H. R.; Davidson, B. L.; Decousus, H.; Gallus, A.; Gent, M.; Piovella, F.; Prins, M. H.; Raskob, G.; Segers, A. E.; Cariou, R.; Leeuwenkamp, O.; Lensing, A. W., Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 2004, 140 (11), 867-73.
100. Buller, H. R.; Davidson, B. L.; Decousus, H.; Gallus, A.; Gent, M.; Piovella, F.; Prins, M. H.; Raskob, G.; van den Berg-Segers, A. E.; Cariou, R.; Leeuwenkamp, O.; Lensing, A. W., Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003, 349 (18), 1695-702.
101. Decousus, H.; Quere, I.; Presles, E.; Becker, F.; Barrellier, M. T.; Chanut, M.; Gillet, J. L.; Guenneguez, H.; Leandri, C.; Mismetti, P.; Pichot, O.; Leizorovicz, A., Superficial venous thrombosis and venous thromboembolism: a large, prospective epidemiologic study. Ann Intern Med 2010, 152 (4), 218-24.
102. Decousus, H.; Prandoni, P.; Mismetti, P.; Bauersachs, R. M.; Boda, Z.; Brenner, B.; Laporte, S.; Matyas, L.; Middeldorp, S.; Sokurenko, G.; Leizorovicz, A., Fondaparinux for the treatment of superficial-vein thrombosis in the legs. N Engl J Med 2010, 363 (13), 1222-32.
103. Yusuf, S.; Mehta, S. R.; Chrolavicius, S.; Afzal, R.; Pogue, J.; Granger, C. B.; Budaj, A.; Peters, R. J.; Bassand, J. P.; Wallentin, L.; Joyner, C.; Fox, K. A., Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006, 354 (14), 1464-76.
104. Yusuf, S.; Mehta, S. R.; Chrolavicius, S.; Afzal, R.; Pogue, J.; Granger, C. B.; Budaj, A.; Peters, R. J.; Bassand, J. P.; Wallentin, L.; Joyner, C.; Fox, K. A., Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 2006, 295 (13), 1519-30.
105. Mehta, S. R.; Granger, C. B.; Eikelboom, J. W.; Bassand, J. P.; Wallentin, L.; Faxon, D. P.; Peters, R. J.; Budaj, A.; Afzal, R.; Chrolavicius, S.; Fox, K. A.; Yusuf, S., Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J Am Coll Cardiol 2007, 50 (18), 1742-51.
106. Schiele, F., Fondaparinux and acute coronary syndromes: update on the OASIS 5-6 studies. Vasc Health Risk Manag 2010, 6, 179-87.
107. Mehta, S. R.; Boden, W. E.; Eikelboom, J. W.; Flather, M.; Steg, P. G.; Avezum, A.; Afzal, R.; Piegas, L. S.; Faxon, D. P.; Widimsky, P.; Budaj, A.; Chrolavicius, S.; Rupprecht, H. J.; Jolly, S.; Granger, C. B.; Fox, K. A.; Bassand, J. P.; Yusuf, S., Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with S T-and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials. Circulation 2008, 118 (20), 2038-46.
108. Steg, P. G.; Jolly, S. S.; Mehta, S. R.; Afzal, R.; Xavier, D.; Rupprecht, H. J.; Lopez-Sendon, J. L.; Budaj, A.; Diaz, R.; Avezum, A.; Widimsky, P.; Rao, S. V.; Chrolavicius, S.; Meeks, B.; Joyner, C.; Pogue, J.; Yusuf, S., Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial. JAMA 2010, 304 (12), 1339-49.
109. A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation. J Thromb Haemost 2004, 2 (1), 47-53.
110. Harenberg, J., Development of idraparinux and idrabiotaparinux for anticoagulant therapy. Thromb Haemost 2009, 102 (5), 811-5.
111. Buller, H. R.; Cohen, A. T.; Davidson, B.; Decousus, H.; Gallus, A. S.; Gent, M.; Pillion, G.; Piovella, F.; Prins, M. H.; Raskob, G. E., Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med 2007, 357 (11), 1094-104.
112. Buller, H. R.; Cohen, A. T.; Davidson, B.; Decousus, H.; Gallus, A. S.; Gent, M.; Pillion, G.; Piovella, F.; Prins, M. H.; Raskob, G. E., Extended prophylaxis of venous thromboembolism with idraparinux. N Engl J Med 2007, 357 (11), 1105-12.
113. Bousser, M. G.; Bouthier, J.; Buller, H. R.; Cohen, A. T.; Crijns, H.; Davidson, B. L.; Halperin, J.; Hankey, G.; Levy, S.; Pengo, V.; Prandoni, P.; Prins, M. H.; Tomkowski, W.; Torp-Pedersen, C.; Wyse, D. G., Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. Lancet 2008, 371 (9609), 315-21.
114. Harenberg, J.; Vukojevic, Y.; Mikus, G.; Joerg, I.; Weiss, C., Long elimination half-life of idraparinux may explain major bleeding and recurrent events of patients from the van Gogh trials. J Thromb Haemost 2008, 6 (5), 890-2.
115. Savi, P.; Herault, J. P.; Duchaussoy, P.; Millet, L.; Schaeffer, P.; Petitou, M.; Bono, F.; Herbert, J. M., Reversible biotinylated oligosaccharides: a new approach for a better management of anticoagulant therapy. J Thromb Haemost 2008, 6 (10), 1697-706.
116. Trellu, M.; Perez, Y.; Ortiz, J.; Cheng, S.; Paty, I., Bioequipotency of idraparinux and biotinylated idraparinux after single dose in healthy adults. Journal of Thrombosis and Haemostasis 2007, 5.
117. Paty, I.; Trellu, M.; Destors, J. M.; Cortez, P.; Boelle, E.; Sanderink, G., Reversibility of the anti-FXa activity of idrabiotaparinux (biotinylated idraparinux) by intravenous avidin infusion. J Thromb Haemost 2010, 8 (4), 722-9.
118. Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis. J Thromb Haemost 2011, 9 (1), 92-9.
119. Buller, H. R.; Gallus, A. S.; Pillion, G.; Prins, M. H.; Raskob, G. E., Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial. Lancet 2011.
120. Di Nisio, M.; Middeldorp, S.; Buller, H. R., Direct thrombin inhibitors. N Engl J Med 2005, 353 (10), 1028-40.
121. (a) Lee, C. J.; Ansell, J. E., Direct thrombin inhibitors. Br J Clin Pharmacol 2011, 72 (4), 581-92
122. (b) Stangier, J.; Rathgen, K.; Stahle, H.; Mazur, D., Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010, 49 (4), 259-68.
123. Greinacher, A.; Warkentin, T. E., The direct thrombin inhibitor hirudin. Thromb Haemost 2008, 99 (5), 819-29.
124. Nutescu, E. A.; Wittkowsky, A. K., Direct thrombin inhibitors for anticoagulation. Ann Pharmacother 2004, 38 (1), 99-109.
125. Petros, S., Lepirudin in the management of patients with heparin-induced thrombocytopenia. Biologics 2008, 2 (3), 481-90.
126. Greinacher, A.; Janssens, U.; Berg, G.; Bock, M.; Kwasny, H.; Kemkes-Matthes, B.; Eichler, P.; Volpel, H.; Potzsch, B.; Luz, M., Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia Study (HAT) investigators. Circulation 1999, 100 (6), 587-93.
127. Lubenow, N.; Eichler, P.; Lietz, T.; Greinacher, A., Lepirudin in patients with heparin-induced thrombocytopenia-results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. J Thromb Haemost 2005, 3 (11), 2428-36.
128. Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation: a pilot study. Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators. Circulation 1997, 96 (3), 769-77.
129. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators. Lancet 1999, 353 (9151), 429-38.
130. Robson, R.; White, H.; Aylward, P.; Frampton, C., Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose, and gender. Clin Pharmacol Ther 2002, 71 (6), 433-9.
131. Fox, I.; Dawson, A.; Loynds, P.; Eisner, J.; Findlen, K.; Levin, E.; Hanson, D.; Mant, T.; Wagner, J.; Maraganore, J., Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans. Thromb Haemost 1993, 69 (2), 157-63.
132. Bittl, J. A.; Strony, J.; Brinker, J. A.; Ahmed, W. H.; Meckel, C. R.; Chaitman, B. R.; Maraganore, J.; Deutsch, E.; Adelman, B., Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators. N Engl J Med 1995, 333 (12), 764-9.
133. Lincoff, A. M.; Kleiman, N. S.; Kottke-Marchant, K.; Maierson, E. S.; Maresh, K.; Wolski, K. E.; Topol, E. J., Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET). Am Heart J 2002, 143 (5), 847-53.
134. Lincoff, A. M.; Bittl, J. A.; Harrington, R. A.; Feit, F.; Kleiman, N. S.; Jackman, J. D.; Sarembock, I. J.; Cohen, D. J.; Spriggs, D.; Ebrahimi, R.; Keren, G.; Carr, J.; Cohen, E. A.; Betriu, A.; Desmet, W.; Kereiakes, D. J.; Rutsch, W.; Wilcox, R. G.; de Feyter, P. J.; Vahanian, A.; Topol, E. J., Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003, 289 (7), 853-63.
135. Lincoff, A. M.; Bittl, J. A.; Kleiman, N. S.; Sarembock, I. J.; Jackman, J. D.; Mehta, S.; Tannenbaum, M. A.; Niederman, A. L.; Bachinsky, W. B.; Tift-Mann, J., 3rd; Parker, H. G.; Kereiakes, D. J.; Harrington, R. A.; Feit, F.; Maierson, E. S.; Chew, D. P.; Topol, E. J., Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial). Am J Cardiol 2004, 93 (9), 1092-6.
136. Stone, G. W.; McLaurin, B. T.; Cox, D. A.; Bertrand, M. E.; Lincoff, A. M.; Moses, J. W.; White, H. D.; Pocock, S. J.; Ware, J. H.; Feit, F.; Colombo, A.; Aylward, P. E.; Cequier, A. R.; Darius, H.; Desmet, W.; Ebrahimi, R.; Hamon, M.; Rasmussen, L. H.; Rupprecht, H. J.; Hoekstra, J.; Mehran, R.; Ohman, E. M., Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006, 355 (21), 2203-16.
137. Singh, S.; Molnar, J.; Arora, R., Efficacy and safety of bivalirudin versus heparins in reduction of cardiac outcomes in acute coronary syndrome and percutaneous coronary interventions. J Cardiovasc Pharmacol Ther 2007, 12 (4), 283-91.
138. Stone, G. W.; Witzenbichler, B.; Guagliumi, G.; Peruga, J. Z.; Brodie, B. R.; Dudek, D.; Kornowski, R.; Hartmann, F.; Gersh, B. J.; Pocock, S. J.; Dangas, G.; Wong, S. C.; Kirtane, A. J.; Parise, H.; Mehran, R., Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008, 358 (21), 2218-30.
139. Stone, G. W.; Witzenbichler, B.; Guagliumi, G.; Peruga, J. Z.; Brodie, B. R.; Dudek, D.; Kornowski, R.; Hartmann, F.; Gersh, B. J.; Pocock, S. J.; Dangas, G.; Wong, S. C.; Fahy, M.; Parise, H.; Mehran, R., Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet 2011, 377 (9784), 2193-204.
140. White, H., Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet 2001, 358 (9296), 1855-63.
141. Gustafsson, D.; Elg, M., The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review. Thromb Res 2003, 109 Suppl 1, S9-15.
142. Sarich, T. C.; Osende, J. I.; Eriksson, U. G.; Fager, G. B.; Eriksson-Lepkowska, M.; Ohlsson, L.; Carlsson, S.; Wahlander, K.; Gustafsson, D.; Badimon, J. J., Acute antithrombotic effects of ximelagatran, an oral direct thrombin inhibitor, and r-hirudin in a human ex vivo model of arterial thrombosis. J Thromb Haemost 2003, 1 (5), 999-1004.
143. Colwell, C. W., Jr.; Berkowitz, S. D.; Davidson, B. L.; Lotke, P. A.; Ginsberg, J. S.; Lieberman, J. R.; Neubauer, J.; McElhattan, J. L.; Peters, G. R.; Francis, C. W., Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study. J Thromb Haemost 2003, 1 (10), 2119-30.
144. Francis, C. W.; Davidson, B. L.; Berkowitz, S. D.; Lotke, P. A.; Ginsberg, J. S.; Lieberman, J. R.; Webster, A. K.; Whipple, J. P.; Peters, G. R.; Colwell, C. W., Jr., Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial. Ann Intern Med 2002, 137 (8), 648-55.
145. Francis, C. W.; Berkowitz, S. D.; Comp, P. C.; Lieberman, J. R.; Ginsberg, J. S.; Paiement, G.; Peters, G. R.; Roth, A. W.; McElhattan, J.; Colwell, C. W., Jr., Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med 2003, 349 (18), 1703-12.
146. Colwell, C. W., Jr.; Berkowitz, S. D.; Lieberman, J. R.; Comp, P. C.; Ginsberg, J. S.; Paiement, G.; McElhattan, J.; Roth, A. W.; Francis, C. W., Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty. J Bone Joint Surg Am 2005, 87 (10), 2169-77.
147. Eriksson, B. I.; Agnelli, G.; Cohen, A. T.; Dahl, O. E.; Mouret, P.; Rosencher, N.; Eskilson, C.; Nylander, I.; Frison, L.; Ogren, M., Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. Thromb Haemost 2003, 89 (2), 288-96.
148. Eriksson, B. I.; Agnelli, G.; Cohen, A. T.; Dahl, O. E.; Lassen, M. R.; Mouret, P.; Rosencher, N.; Kalebo, P.; Panfilov, S.; Eskilson, C.; Andersson, M.; Freij, A., The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. J Thromb Haemost 2003, 1 (12), 2490-6.
149. Schulman, S.; Wahlander, K.; Lundstrom, T.; Clason, S. B.; Eriksson, H., Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003, 349 (18), 1713-21.
150. Fiessinger, J. N.; Huisman, M. V.; Davidson, B. L.; Bounameaux, H.; Francis, C. W.; Eriksson, H.; Lundstrom, T.; Berkowitz, S. D.; Nystrom, P.; Thorsen, M.; Ginsberg, J. S., Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA 2005, 293 (6), 681-9.
151. Olsson, S. B., Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003, 362 (9397), 1691-8.
152. Albers, G. W.; Diener, H. C.; Frison, L.; Grind, M.; Nevinson, M.; Partridge, S.; Halperin, J. L.; Horrow, J.; Olsson, S. B.; Petersen, P.; Vahanian, A., Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 2005, 293 (6), 690-8.
153. Wallentin, L.; Wilcox, R. G.; Weaver, W. D.; Emanuelsson, H.; Goodvin, A.; Nystrom, P.; Bylock, A., Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet 2003, 362 (9386), 789-97.
154. Swan, S. K.; Hursting, M. J., The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000, 20 (3), 318-29.
155. Lewis, B. E.; Wallis, D. E.; Berkowitz, S. D.; Matthai, W. H.; Fareed, J.; Walenga, J. M.; Bartholomew, J.; Sham, R.; Lerner, R. G.; Zeigler, Z. R.; Rustagi, P. K.; Jang, I. K.; Rifkin, S. D.; Moran, J.; Hursting, M. J.; Kelton, J. G., Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001, 103 (14), 1838-43.
156. Lewis, B. E.; Wallis, D. E.; Leya, F.; Hursting, M. J.; Kelton, J. G., Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 2003, 163 (15), 1849-56.
157. Jang, I. K.; Lewis, B. E.; Matthai, W. H., Jr.; Kleiman, N. S., Argatroban anticoagulation in conjunction with glycoprotein IIb/IIIa inhibition in patients undergoing percutaneous coronary intervention: an open-label, nonrandomized pilot study. J Thromb Thrombolysis 2004, 18 (1), 31-7.
158. Cruz-Gonzalez, I.; Sanchez-Ledesma, M.; Baron, S. J.; Healy, J. L.; Watanabe, H.; Osakabe, M.; Yeh, R. W.; Jang, I. K., Efficacy and safety of argatroban with or without glycoprotein IIb/IIIa inhibitor in patients with heparin induced thrombocytopenia undergoing percutaneous coronary intervention for acute coronary syndrome. J Thromb Thrombolysis 2008, 25 (2), 214-8.
159. Rossig, L.; Genth-Zotz, S.; Rau, M.; Heyndrickx, G. R.; Schneider, T.; Gulba, D. C.; Desaga, M.; Buerke, M.; Harder, S.; Zeiher, A. M., Argatroban for elective percutaneous coronary intervention: the ARG-E04 multi-center study. Int J Cardiol 2011, 148 (2), 214-9.
160. LaMonte, M. P.; Nash, M. L.; Wang, D. Z.; Woolfenden, A. R.; Schultz, J.; Hursting, M. J.; Brown, P. M., Argatroban anticoagulation in patients with acute ischemic stroke (ARGIS-1): a randomized, placebo-controlled safety study. Stroke 2004, 35 (7), 1677-82.
161. Barreto, A. D.; Alexandrov, A. V.; Lyden, P.; Lee, J.; Martin-Schild, S.; Shen, L.; Wu, T. C.; Sisson, A.; Pandurengan, R.; Chen, Z.; Rahbar, M. H.; Balucani, C.; Barlinn, K.; Sugg, R. M.; Garami, Z.; Tsivgoulis, G.; Gonzales, N. R.; Savitz, S. I.; Mikulik, R.; Demchuk, A. M.; Grotta, J. C., The Argatroban and Tissue-Type Plasminogen Activator Stroke Study: Final Results of a Pilot Safety Study. Stroke 2012.
162. Stangier, J.; Rathgen, K.; Stahle, H.; Gansser, D.; Roth, W., The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007, 64 (3), 292-303.
163. Eisert, W. G.; Hauel, N.; Stangier, J.; Wienen, W.; Clemens, A.; van Ryn, J., Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin. Arterioscler Thromb Vasc Biol 2010, 30 (10), 1885-9.
164. Wienen, W.; Stassen, J. M.; Priepke, H.; Ries, U. J.; Hauel, N., In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost 2007, 98 (1), 155-62.
165. Eriksson, B. I.; Dahl, O. E.; Rosencher, N.; Kurth, A. A.; van Dijk, C. N.; Frostick, S. P.; Prins, M. H.; Hettiarachchi, R.; Hantel, S.; Schnee, J.; Buller, H. R., Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007, 370 (9591), 949-56.
166. Eriksson, B. I.; Dahl, O. E.; Huo, M. H.; Kurth, A. A.; Hantel, S.; Hermansson, K.; Schnee, J. M.; Friedman, R. J., Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RENOVATE II*). A randomised, double-blind, non-inferiority trial. Thromb Haemost 2011, 105 (4), 721-9.
167. Eriksson, B. I.; Dahl, O. E.; Rosencher, N.; Kurth, A. A.; van Dijk, C. N.; Frostick, S. P.; Kalebo, P.; Christiansen, A. V.; Hantel, S.; Hettiarachchi, R.; Schnee, J.; Buller, H. R., Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007, 5 (11), 2178-85.
168. Ginsberg, J. S.; Davidson, B. L.; Comp, P. C.; Francis, C. W.; Friedman, R. J.; Huo, M. H.; Lieberman, J. R.; Muntz, J. E.; Raskob, G. E.; Clements, M. L.; Hantel, S.; Schnee, J. M.; Caprini, J. A., Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009, 24 (1), 1-9.
169. Wolowacz, S. E.; Roskell, N. S.; Plumb, J. M.; Caprini, J. A.; Eriksson, B. I., Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Thromb Haemost 2009, 101 (1), 77-85.
170. Schulman, S.; Kearon, C.; Kakkar, A. K.; Mismetti, P.; Schellong, S.; Eriksson, H.; Baanstra, D.; Schnee, J.; Goldhaber, S. Z., Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009, 361 (24), 2342-52.
171. Schulman, S., Kakkar, A.K., Schellong, S.M., Goldhaber, S.Z., Henry, E., Mismetti, P., Christiansen, A.V., Schnee, J., Kearon, C., A Randomized Trial of Dabigatran Versus Warfarin in the Treatment of Acute Venous Thromboembolism (RE-COVER II). Blood 2011, 118 (21).
172. Schulman, S., Eriksson, H., Goldhaber, S.Z., Kakkar, A.K.L., Kearon, C., Kvamme, A.M., Mismetti, P., Schellong, S., Schnee, J., Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism. Journal of Thrombosis and Haemostasis 2011, 9 (s2), 731.
173. Schulman, S., Baanstra, D., Eriksson, H., Goldhaber, S., Kakkar, A., Kearon, C., Mismetti, P., Schellong, S., Schnee, J., the RE-SONATE Study Group, Dabigatran versus placebo for extended maintenance therapy of venous thromboembolism. Journal of Thrombosis and Haemostasis 2011, 9 (s2), 22.
174. Connolly, S. J.; Ezekowitz, M. D.; Yusuf, S.; Eikelboom, J.; Oldgren, J.; Parekh, A.; Pogue, J.; Reilly, P. A.; Themeles, E.; Varrone, J.; Wang, S.; Alings, M.; Xavier, D.; Zhu, J.; Diaz, R.; Lewis, B. S.; Darius, H.; Diener, H. C.; Joyner, C. D.; Wallentin, L., Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361 (12), 1139-51.
175. Legrand, M.; Mateo, J.; Aribaud, A.; Ginisty, S.; Eftekhari, P.; Huy, P. T.; Drouet, L.; Payen, D., The use of dabigatran in elderly patients. Arch Intern Med 2011, 171 (14), 1285-6.
176. Eikelboom, J. W.; Wallentin, L.; Connolly, S. J.; Ezekowitz, M.; Healey, J. S.; Oldgren, J.; Yang, S.; Alings, M.; Kaatz, S.; Hohnloser, S. H.; Diener, H. C.; Franzosi, M. G.; Huber, K.; Reilly, P.; Varrone, J.; Yusuf, S., Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011, 123 (21), 2363-72.
177. Jacobs, J. M.; Stessman, J., New anticoagulant drugs among elderly patients is caution necessary?: Comment on "The use of dabigatran in elderly patients". Arch Intern Med 2011, 171 (14), 1287-8.
178. Oldgren, J.; Budaj, A.; Granger, C. B.; Khder, Y.; Roberts, J.; Siegbahn, A.; Tijssen, J. G.; Van de Werf, F.; Wallentin, L., Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J 2011, 32 (22), 2781-9.
179. Ellis, D. J.; Usman, M. H.; Milner, P. G.; Canafax, D. M.; Ezekowitz, M. D., The first evaluation of a novel vitamin K antagonist, tecarfarin (ATI-5923), in patients with atrial fibrillation. Circulation 2009, 120 (12), 1029-35, 2 p following 1035.
180. Bavisotto, L. M.; Ellis, D. J.; Milner, P. G.; Combs, D. L.; Irwin, I.; Canafax, D. M., Tecarfarin, a novel vitamin K reductase antagonist, is not affected by CYP2C9 and CYP3A4 inhibition following concomitant administration of fluconazole in healthy participants. J Clin Pharmacol 2011, 51 (4), 561-74.
181. Bowersox, S. S.; Canafax, D.; Druzgala, P.; Milner, P.; Weitz, J. I., Antithrombotic activity of the novel oral anticoagulant, Tecarfarin [Sodium 3-[4-((1, 1, 1, 3, 3, 3-hexafluoro-2-methylpropan-2-yloxy) carbonyl) benzyl]-2-oxo-2H-chromen-4-olate] in animal models. Thromb Res 2010, 126 (5), e383-8.
182. Baker, W. L.; Cios, D. A.; Sander, S. D.; Coleman, C. I., Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm 2009, 15 (3), 244-52.